Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 7-Ethyl-10-Hydroxycamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 17/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29359781 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29787648 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL13420265 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL733477 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL16072280 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29354078 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL27680702 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL28292269 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL1454961 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL30739326 | 0.95 | MEN1 (0.91) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6582 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4743124-A1 | DE-N-ACETYLATED POLYSIALIC ACID (DPSA) BINDING AGENT, CONJUGATES, AND METHOD OF USING SAME | Saccharo, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| CN-122055170-A | Des-N-acetylated polysialic acid (dPSA) binders, conjugates, and methods of use thereof | 萨克罗有限公司 | 2026-05-15 | — | — | CN | claimed |
| WO-2026098715-A1 | ANTIBODY-DRUG CONJUGATE CONTAINING ANTI-CLDN6 ANTIBODY | 智泽童康(广州)生物科技有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| EP-4740956-A1 | PHARMACEUTICAL COMBINATION FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2026-05-13 | — | — | EP | claimed |
| CN-122005464-A | Paclitaxel precursor nano-drug and preparation method and application thereof | 浙江理工大学 | 2026-05-12 | — | — | CN | claimed |
| EP-4732850-A1 | ANTIBODY-DRUG CONJUGATES AND THEIR USES | Antelope Therapeutics SAS (FR) | 2026-04-29 | — | — | EP | claimed |
| EP-4731263-A1 | BIO-CONJUGATES FOR ONCOLOGY | RDP Pharma AG (CH) | 2026-04-29 | — | — | EP | claimed |
| US-12605462-B2 | Porous silicon nanoparticle-based drug delivery system inducing reactive oxygen species and self-activation thereof, and method for preparing same | UNIVERSITY-INDUSTRY COOPERATION GROUP OF KYUNG HEE UNIVERSITY (KR) | 2026-04-21 | — | — | US | claimed |
| WO-2000021370-A1 | OLIGONUCLEOTIDE DELIVERY SYSTEMS FOR CAMPTOTHECINS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2000-04-20 | — | — | WO | claimed |
| US-6011042-A | POLYMERIC PRODRUGS ARE PREFERABLY ESTERS OF HYDROXYL-CONTAINING AROMATIC COMPOUNDS AND ARE FORMED BY REACTING A DESIRED AROMATIC, HYDROXYL-CONTAINING COMPOUND WITH A SUBSTANTIALLY NON-ANTIGENIC POLYMER | ENZON, INC. (US) | 2000-01-04 | — | — | US | claimed |
| WO-1999048503-A1 | ANTITUMOR COMPOSITION CONTAINING A SYNERGISTIC COMBINATION OF AN ANTHRACYCLINE DERIVATIVE WITH A CAMPTOTHECIN DERIVATE | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-09-30 | — | — | WO | claimed |
| WO-1999017804-A1 | POLYMERIC DERIVATIVES OF CAMPTOTHECINS | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-04-15 | — | — | WO | claimed |
| US-5674874-A | ANTICANCER AGENT | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1997-10-07 | — | — | US | claimed |
| US-5674873-A | IN SOLUTION OF DIMETHYLISOSORBIDE WITH CITRIC ACID OR A MIXTURE OF CITRIC ACID AND TAUROCHOLIC ACID | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1997-10-07 | — | — | US | claimed |
| EP-0735876-A1 | LACTONE STABLE FORMULATION OF 10-HYDROXY 7-ETHYL CAMPTOTHECIN | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1996-10-09 | — | — | EP | claimed |
| US-5447936-A | Anticarcinogenic agents in dimethylacetamide solutions and carboxylic acids | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1995-09-05 | — | — | US | claimed |
| WO-1995017187-A1 | LACTONE STABLE FORMULATION OF 10-HYDROXY 7-ETHYL CAMPTOTHECIN | BIONUMERIK PHARMACEUTICALS, INC. (US) | 1995-06-29 | — | — | WO | claimed |
| US-4473692-A | Camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1984-09-25 | — | — | US | claimed |